Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptoms

被引:40
作者
Strbian, Daniel [1 ]
Piironen, Katja [1 ]
Meretoja, Atte [1 ]
Sairanen, Tiina [1 ]
Putaala, Jukka [1 ]
Tiainen, Marjaana [1 ]
Artto, Ville [1 ]
Rantanen, Kirsi [1 ]
Happola, Olli [1 ]
Kaste, Markku [1 ]
Lindsberg, Perttu J. [1 ,2 ,3 ]
机构
[1] Helsinki Univ Cent Hosp, Dept Neurol, Helsinki 00290, Finland
[2] Biomed Helsinki, Res Programs Unit, Helsinki, Finland
[3] Univ Helsinki, Dept Clin Neurosci, Helsinki, Finland
基金
芬兰科学院;
关键词
acute stroke therapy; cerebral infarction; ischemic stroke; rtPA; thrombolysis; tPA; TISSUE-PLASMINOGEN ACTIVATOR; OF-HEALTH STROKE; NEUROLOGICAL-DISORDERS; NATIONAL-INSTITUTE; CT-ANGIOGRAPHY; OUTCOMES; THERAPY; TRIAL; ELIGIBILITY; SCALE;
D O I
10.1111/j.1747-4949.2012.00808.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Thrombolysis of ischemic stroke patients presenting with mild symptoms is controversial. Aim We aimed to describe the clinical outcome and frequency of infarcts and symptomatic intracerebral hemorrhages on follow-up imaging of such thrombolysis-treated patients. Methods Our cohort included 1398 consecutive ischemic stroke patients treated with intravenous thrombolysis at the Helsinki University Central Hospital, years 1995-2010. We analyzed the patients according to baseline National Institutes of Health Stroke Scale: 2, 3-4, 5-6, and >6. In our institution, visualization of an artery occlusion or perfusion deficit is required for thrombolysis with National Institutes of Health Stroke Scale2. We used univariate and multivariable methods to describe the cohort and study associations between the variables. Excellent three-month outcome was defined as modified Rankin Scale 0-1. Results Fifty-eight (4 center dot 1%) patients were treated with National Institutes of Health Stroke Scale2, another 194 (13 center dot 6%) with 3-4 points, and 236 (16 center dot 5%) with 5-6 points. With National Institutes of Health Stroke Scale2, 45 (78%) of the patients had excellent three-month outcome, achieved in 116 (59%) patients with National Institutes of Health Stroke Scale 3-4, in 130 (55%) with National Institutes of Health Stroke Scale 5-6, and in 241 (26%) with National Institutes of Health Stroke Scale>6. Frequencies of symptomatic intracerebral hemorrhage (European Cooperative Acute Stroke Study-2) were 0%, 2 center dot 6%, 2 center dot 1%, and 8 center dot 1%, and visible infarcts on follow-up imaging 48%, 43%, 48%, and 74%, respectively. In patients with baseline National Institutes of Health Stroke Scale6, poor outcome was associated with previous stroke, diabetes, elevated admission blood glucose, and development of intracerebral hemorrhage. Conclusions Half of patients presenting with National Institutes of Health Stroke Scale 0-6 developed an infarction despite thrombolysis, and 40% had poor outcome, which was associated with glucose metabolism and hemorrhagic complications. Managing thrombolysis candidates with mild symptoms warrants individual consideration often supported by multimodal imaging.
引用
收藏
页码:293 / 299
页数:7
相关论文
共 25 条
  • [1] ATLANTIS trial - Results for patients treated within 3 hours of stroke onset
    Albers, GW
    Clark, WM
    Madden, KP
    Hamilton, SA
    [J]. STROKE, 2002, 33 (02) : 493 - 495
  • [2] Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility
    Barber, PA
    Zhang, J
    Demchuk, AM
    Hill, MD
    Buchan, AM
    [J]. NEUROLOGY, 2001, 56 (08) : 1015 - 1020
  • [3] Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms
    Baumann, CR
    Baumgartner, RW
    Gandjour, J
    von Büdingen, HC
    Siegel, AM
    Georgiadis, D
    [J]. STROKE, 2006, 37 (05) : 1332 - 1333
  • [4] Recombinant tissue plasminogen activator for minor strokes: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Experience
    Broderick, JP
    Brott, T
    DeGraba, T
    Fagan, SC
    Frankel, MR
    Grotta, JC
    Haley, EC
    Hamilton, S
    Kwiatkowski, T
    Levine, SR
    Lewandowski, CA
    Lin, Y
    Libman, R
    Lu, M
    Lyden, P
    Marler, JR
    Morgenstern, L
    Patel, S
    Sanders, C
    Tilley, BC
    [J]. ANNALS OF EMERGENCY MEDICINE, 2005, 46 (03) : 243 - 252
  • [5] Reasons for exclusion from thrombolytic therapy following acute ischemic stroke
    Cocho, D
    Belvís, R
    Martí-Fàbregas, J
    Molina-Porcel, L
    Díaz-Manera, J
    Aleu, A
    Pagonabarraga, J
    García-Bargo, D
    Mauri, A
    Martí-Vilalta, JL
    [J]. NEUROLOGY, 2005, 64 (04) : 719 - 720
  • [6] Interconversion of the National Institutes of Health Stroke Scale and Scandinavian Stroke Scale in Acute Stroke
    Gray, Laura J.
    Ali, Myzoon
    Lyden, Patrick D.
    Bath, Philip M. W.
    [J]. JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2009, 18 (06) : 466 - 468
  • [7] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
    Hacke, W
    Kaste, M
    Fieschi, C
    von Kummer, R
    Davalos, A
    Meier, D
    Larrue, V
    Bluhmki, E
    Davis, S
    Donnan, G
    Schneider, D
    Diez-Tejedor, E
    Trouillas, P
    [J]. LANCET, 1998, 352 (9136) : 1245 - 1251
  • [8] HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
  • [9] Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial
    Ingall, TJ
    O'Fallon, WM
    Asplund, K
    Goldfrank, LR
    Hertzberg, VS
    Louis, TA
    Christianson, TJH
    [J]. STROKE, 2004, 35 (10) : 2418 - 2424
  • [10] Utilization of intravenous tissue plasminogen activator for acute ischemic stroke
    Katzan, IL
    Hammer, MD
    Hixson, ED
    Furlan, AJ
    Abou-Chebl, A
    Nadzam, DM
    [J]. ARCHIVES OF NEUROLOGY, 2004, 61 (03) : 346 - 350